Eli Lilly and Company has entered into an underwriting agreement for the issuance and sale of various debt securities totaling approximately $6.71 billion. This includes $750 million in Floating Rate Notes due 2028 and several series of fixed-rate notes with varying maturities and interest rates, ranging from 4.000% to 5.650%. The offering was registered under a Form S-3 registration statement.
The notes will provide Eli Lilly with significant capital, with net proceeds realized after underwriting discounts. The company retains the option to redeem the fixed-rate notes under specified conditions, while the floating rate notes cannot be redeemed prior to maturity. An Event of Default could lead to the immediate repayment of principal for any affected series of notes.
linkAug 20, 2025 16:16:08
Eli Lilly and Company reported a 38% increase in revenue for the second quarter of 2025, reaching $15.56 billion, primarily driven by strong sales of its products Zepbound and Mounjaro. The company raised its full-year revenue guidance by $1.5 billion to a range of $60 billion to $62 billion, and adjusted its earnings per share (EPS) guidance to between $20.85 and $22.10. The net income for the quarter was $5.66 billion, translating to an EPS of $6.29, a significant increase from $3.28 in the same quarter of the previous year.
The company's key products contributed to this growth, with Mounjaro revenue increasing by 68% to $5.20 billion and Zepbound revenue rising by 172% to $3.38 billion. Eli Lilly also reported a gross margin of 84.3%, up 3.5 percentage points from the prior year, reflecting improved production costs. Research and development expenses increased by 23% to $3.34 billion, as the company continued to invest in its product pipeline, which includes promising developments in obesity and diabetes treatments.
linkAug 07, 2025 07:05:40
Eli Lilly and Company announced its financial results for the first quarter of 2025, reporting a revenue increase of 45% to $12.73 billion, primarily driven by strong sales of its products Mounjaro and Zepbound. The company also noted a 23% increase in reported net income to $2.76 billion and a 23% rise in earnings per share (EPS) to $3.06. The growth in revenue was supported by a 53% increase in volume, despite some offset from lower realized prices and unfavorable foreign exchange rates.
In addition to financial highlights, Lilly reported progress in its pipeline, including positive Phase 3 trial results for orforglipron, an oral GLP-1 agonist for Type 2 diabetes. The company reaffirmed its revenue guidance for 2025, expecting it to remain between $58.0 billion and $61.0 billion. However, it updated its EPS guidance, now projected to be between $20.17 and $21.67 on a reported basis, reflecting the impact of acquired in-process research and development charges.
linkMay 01, 2025 07:03:11
Eli Lilly and Company announced its Q4 2024 financial results, highlighting a revenue increase of 45% to $13.53 billion, driven by strong sales of Mounjaro and Zepbound. The company's earnings per share (EPS) also saw significant growth, rising 102% to $4.88 on a reported basis. Additionally, Lilly received FDA approvals for new indications of Zepbound and Omvoh, and it is moving forward with the acquisition of Scorpion Therapeutics' PI3Kα inhibitor program, reflecting a robust pipeline and commitment to innovation.
However, the company faced challenges as lower realized prices negatively impacted revenue growth, particularly for Mounjaro and Trulicity. Research and development expenses increased by 18%, indicating higher investment in future projects, while the company reported asset impairment and restructuring charges of $344 million. Despite these hurdles, Lilly plans to continue expanding its manufacturing capacity with a $3 billion investment and has announced a $15 billion share repurchase program alongside a significant dividend increase.
linkFeb 06, 2025 07:05:12
Eli Lilly and Company announced that it anticipates approximately $45.0 billion in revenue for the full year of 2024, which marks a 32% increase compared to the previous year. The company also projects 2025 revenue to be between $58.0 billion and $61.0 billion, reflecting continued growth. Key contributors to this revenue include strong sales from Mounjaro and Zepbound, alongside solid performance in oncology, immunology, and neuroscience medicines. The Q4 2024 revenue is expected to be about $13.5 billion, showing a 45% growth from Q4 2023, although this figure is approximately $400 million below earlier guidance for the quarter.
On the downside, the expected revenue for 2024 is about 3% lower than previous guidance, primarily due to slower-than-anticipated growth in the U.S. incretin market and lower channel inventory at year-end. Despite the overall positive outlook, the company acknowledged challenges in meeting prior revenue expectations for Q4 2024, which may impact investor sentiment. Lilly's CEO noted the need for continued manufacturing improvements and adjustments in response to market dynamics to achieve the outlined growth targets.
linkJan 14, 2025 09:05:19
Eli Lilly and Company has elected Jon Moeller, the CEO of Procter & Gamble, to its board of directors, effective December 1, 2024. His extensive experience in leadership and strategic operations is expected to bring valuable insights to the board. Moeller will also serve on the Audit Committee and the Directors and Corporate Governance Committee, with plans to stand for election by shareholders in May 2026. The company expressed optimism about his contributions to their ongoing growth and operational excellence.
Conversely, Karen Walker will resign from her position on the board effective December 31, 2024, after serving since 2018. While her departure marks the end of her tenure, she will continue to collaborate with Lilly on digital commercial activities in 2025. The company has acknowledged Walker's significant contributions and mentorship during her time on the board, particularly in brand-building and talent development, highlighting her role in Lilly’s growth during a pivotal period.
linkNov 19, 2024 16:49:17
Eli Lilly announced a 20% increase in revenue for Q3 2024, largely driven by strong sales of new products Mounjaro and Zepbound. Excluding prior year revenue from the olanzapine portfolio, total revenue rose by 42%. The company also reported positive developments in clinical trials for tirzepatide and other products, as well as regulatory approvals for Ebglyss and Kisunla, enhancing its product portfolio. Additionally, Lilly's gross margin improved, and net income turned positive compared to a loss in the same quarter last year.
On the downside, revenue from Trulicity declined by 22%, reflecting competitive pressures. The company incurred significant acquired in-process research and development charges, impacting earnings per share. Furthermore, while U.S. revenue increased significantly, international revenue saw a decrease of 12%, highlighting challenges in foreign markets. Lilly also faced inventory issues in the wholesaler channel, which negatively affected sales of Mounjaro and Zepbound.
linkOct 30, 2024 07:05:55
Eli Lilly and Company has announced the appointment of Lucas Montarce as its new executive vice president and chief financial officer. Montarce, who has been with the company since 2001, brings extensive experience in finance leadership roles, having worked in various capacities across the organization. The CEO expressed confidence in Montarce's abilities to enhance the company's financial strategies and support its growth as it continues to expand globally.
Montarce's commitment to building on Lilly's strong financial foundation and delivering long-term value is a positive sign for stakeholders. His diverse background within the company and his recent leadership in the Spain, Portugal, and Greece hub indicate that he is well-equipped to navigate the challenges ahead. Overall, this leadership change is seen as a strategic move to bolster Lilly's ongoing success in the healthcare sector.
linkSep 09, 2024 07:03:46
Eli Lilly and Company has announced the retirement of Marschall S. Runge from its Board of Directors, effective August 31, 2024. Dr. Runge has been a valuable member of the board since 2013, contributing his extensive experience in medicine and research, particularly in diabetes and obesity treatments. His departure marks the end of a significant tenure during which he played a key role in guiding the company's health care initiatives. The company expressed gratitude for his service and wished him well in his future endeavors in health care and education.
Despite the retirement of a seasoned board member, Lilly continues to emphasize its commitment to innovation in medicine and improving patient care. The company has a strong focus on addressing major health challenges such as diabetes, obesity, Alzheimer's disease, and cancer. With a history of nearly 150 years in the industry, Lilly remains dedicated to advancing health solutions and ensuring access to its medicines for millions of people worldwide.
linkAug 16, 2024 16:16:48
Eli Lilly's Q2 2024 revenue surged 36%, driven by strong sales of Mounjaro, Zepbound, and Verzenio. The company raised its full-year revenue guidance by $3 billion, reflecting confidence in ongoing growth. Earnings per share also rose significantly, showcasing robust financial health. Key approvals for Alzheimer’s and lymphoma treatments were achieved, alongside pipeline advancements for obesity and heart failure therapies. However, potential supply tightness for certain products may pose challenges ahead.
linkAug 08, 2024 07:04:30